Researchers point to improvements in blood pressure, lipid profiles, and vascular inflammation as key contributors
The Precision Folic Acid Trial (PFAT-Hcy) is specifically testing genotype-adjusted folic acid dosing, built on earlier findings such as the China Stroke Primary Prevention Trial, which linked a roughly 20% reduction in homocysteine to a meaningful drop in stroke risk
As an added advantage, GLP-1s are not themselves addictive and dont trigger withdrawal
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease
After a month-long break, a conservative approach often involves restarting at a lower dosetypically the starting dose of 2.5 mg weekly or one step below the previous maintenance dosethen re-escalating according to the standard titration schedule
K., & Lu, R.-B